Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine

Lignende værker

• Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
  af: Greene, Julia, et al.
  Udgivet: (2014)
• Phase Ib Trial of Folate Binding Protein (FBP)-Derived Peptide Vaccines, E39 and an Attenuated Version, E39′: An Analysis of Safety and immune Response
  af: Vreeland, Timothy J., et al.
  Udgivet: (2018)
• Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
  af: Greene, Julia, et al.
  Udgivet: (2014)
• Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
  af: Jackson, Doreen O., et al.
  Udgivet: (2016)
• Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development
  af: Berry, JS, et al.
  Udgivet: (2017)